Background and
purpose: Docetaxel plus
prednisone chemotherapy can improve the
patients '
survival for castrate-resistant
prostate cancer .
Angiogenesis inhibitors can also inhibit the
growth of
tumor . The curative effect of combined
treatment is still not clear. This study aimed to evaluate the
efficacy of
docetaxel plus
prednisone combined with
thalidomide in treating castrate-resistant
prostate cancer (CRPC)
patients with
bone metastasis .
Methods: A total number of 78 CRPC
patients were selected in Fuzhou
General Hospital from Dec. 2008 to Jun. 2015. Seventy-eight
patients were divided into two groups 40
patients in
chemotherapy group (
docetaxel plus
prednisone ) and 38
patients in combined
treatment group (
docetaxel plus
prednisone combined with
thalidomide ). A total number of 78 subjects were evaluated by the effective rate, the remission rate of
bone pain , the
prostate specific antigen (PSA) progression-free surviv-al, the overall
survival and adverse effect.
Results: The response rate (65.79%) and the remission rate of
bone pain (86.84%) in combined
treatment group were both higher than those in
chemotherapy group (40.00% and 60.00%, P0.05). The rates of
adverse effects including
peripheral neuritis and
lethargy in combined
treatment group (26.32% and 55.26%) were higher than those in
chemotherapy group (5.00% and 17.50%, P<0.05).
Conclusion: Thalidomide combined with
docetaxel plus
prednisone in CRPC
patients with
bone metastasis can prolong the PSA
progression-free survival and overall
survival . The
adverse effects are mild. It may become a new choice of
treatment for CRPC.